Appointments

The Canadian Institute for Advanced Research announces the appointment of Dr. Alan Bernstein as the Institute’s new president and CEO commencing May 1, 2012. Most recently, Dr. Bernstein was executive director of the Global HIV Vaccine Enterprise in New York, an international alliance of researchers and funders charged with accelerating the search for an HIV vaccine. From 2000 to 2007, Dr. Bernstein served as the inaugural president of the Canadian Institutes of Health Research, Canada’s federal agency for the support of health research, where he led the transformation of health research in Canada.

Amorfi x Life Sciences has appointed Lynda Covello as vice-president of Strategic Alliances. Covello is a seasoned executive with more than 20 years experience in the biotech and biopharma sector where she has acted as consultant, counsel and senior executive, and recognized as an expert in managing intellectual property and licensing technology globally. Additionally, she is a member of the Licensing Executives Society International (LESI) where she has held many portfolios, most recently that of chair of the LESI Standard Licensing Agreements Committee. Her other roles include being a member of the National Knowledge and Intellectual Property Management Task Force in the U.S., and an instructor in its Executive IP Education programs. She is a graduate of the University of Toronto where she specialized in International Relations. She obtained her LL.B. and LL.M. from Osgoode Hall Law School.

BC Advantage Funds announces that Robert W. Rieder has joined its board of directors. Rieder is chairman of the board of Cardiome Pharma Corp. and previously served as Cardiome’s chief executive offi cer from 1998 to 2009. He has extensive experience in venture capital and the operational management of life science and technology companies. Prior to joining Cardiome, he was vice-president at MDS Ventures Pacifi c Inc., the Vancouver-based affi liate of MDS Capital Corp., and has served as a director for nine public and private technology companies. Rieder has also acted as chief operating offi cer for DBA Telecom Inc., and CEO for Synapse Technologies Inc. He holds a MBA degree from the University of Western Ontario.

Medical diagnostic company Miraculins Inc. announces that distinguished U.S. Cardiologist Dr. Henry A. Solomon has been appointed to the PreVu Medical advisory board. Dr. Solomon received his MD from Columbia University College of Physicians and Surgeons (New York, NY), completed his internship and residency at Montefi ore Hospital and Medical Centre (New York, NY), and his Cardiology Fellowship at the New York Hospital - Cornell Medical Center (New York, NY). He is a Diplomate of both the American Board of Internal Medicine and the American Board of Cardiovascular Disease. He was most recently the chief medical offi cer, business development, of the American College of Cardiology. He continues to serve as senior medical advisor to the American College of Cardiology (which publishes the prestigious, peer reviewed Journal of the American College of Cardiology), as well as Chair of the College’s Professional and Corporate Consortium.

Antonella Mancuso has been promoted to president, Global Commercial Operations and chief manufacturing offi cer, of Patheon. Ms. Mancuso will assume responsibility for all of Patheon’s commercial operating units in North America and Europe. In her previous role as senior vice-president and managing director European Operations, she managed the company’s commercial manufacturing operations outside of North America. Mancuso joined Patheon in 2001 as production manager of Patheon’s facility in Monza, Italy, becoming site director in June 2002. Prior to joining Patheon, Mancuso held progressively senior roles in production and manufacturing during her six years at Bristol-Myers Squibb in Italy. She has also worked at Select Pharma and Bioprogress. She holds a degree in Pharmaceutical Chemistry and Technology from La Sapienza University of Rome.

John Helou has been named president of Pfi zer Canada Inc. Helou, a veteran of more than 25 years in the pharmaceutical industry and head of the Pfi zer Specialty Care Business Unit (SCBU) for Canada and Puerto Rico, succeeds Paul Lévesque, who has been named Chief Marketing Offi cer for Pfi zer Primary Care in the United States. Mr. Lévesque will be moving to Pfi zer headquarters in New York City to take up that position. While taking this expanded leadership position in Canada, Mr. Helou will maintain his role as head of the SCBU. He is based at the company’s Canadian headquarters offi ce in Kirkland, QC. Helou began his career as a chemical engineer with DuPont Canada in 1980, moving fi ve years later to the company’s pharmaceutical business where he took positions of increasing responsibility in sales, marketing, strategic planning and business development in Canada, the U.S. and at the global level. In 1997, Helou set up and became general manager of Agouron Canada, the Canadian operations of a start-up biotech company specializing in HIV/AIDS and oncology treatments. Agouron was subsequently acquired by Pfi zer and the business operations transferred in 2003, at which time he was appointed Pfi zer Canada’s director of Sales for its Specialty Business. In 2006 he was named vice-president, Public Affairs and Stakeholder Relations, before being named head of the SCBU when it was formed in 2009.

MethylGene Inc. has appointmented Dr. Henry J. Fuchs to its board of directors. Dr. Fuchs is currently executive vice-president and chief medical offi cer of BioMarin Pharmaceutical Inc. From 2005 to 2009, he was executive vice-president and chief medical offi cer of Onyx Pharmaceuticals, overseeing expanded development of the kinase inhibitor Nexavar and other key development programs. From 1996 to 2005, he served in multiple roles of increasing responsibility at Ardea Biosciences, fi rst as vice-president, Clinical Affairs, then as president and chief operating offi cer, and fi nally as CEO. From 1987 to 1996, Dr. Fuchs held various positions at Genentech where, among other responsibilities, he led the clinical program that resulted in the approval of Pulmozyme. Dr. Fuchs was also responsible for the Phase 3 development program that led to the approval of Herceptin to treat metastatic breast cancer. Dr. Fuchs received an M.D. degree from George Washington University and a B.A. in biochemical sciences from Harvard University.

The Perfect Combination.

Detergents To Maximize Your Miele Lab Washer.

Our range of professional cleaning detergents delivers residue-free results, extended life of your laboratory glassware and proper care for your Miele Lab Washer. With decades of experience, the end results are cleaner than clean. Experience it for yourself today.

mieleprofessional.ca

Manufacturer direct sales and service available: 1-888-325-3957 Vancouver • Calgary • Edmonton • London • Toronto • Kingston • Ottawa • Montreal